UK Medicines Information
enzalutamide (Xtandi) not recommended for use within NHSScotland
Information type:
Drug best practice guidance
Source:
Scottish Medicines Consortium
Specialities:
Cancers | Renal and urologic disorders
Summary
The SMC does not recommend use of enzalutamide for the treatment of men with high-risk non-metastatic castration-resistant prostate cancer (CRPC). The submitting company’s justification of treatment cost in relation to its health benefit was not sufficient to gain acceptance.
UKMi comment
Similarly, NICE does not recommend enzalutamide for this indication.
Related links:
NICE TA580